In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Revance Therapeutics (RVNC – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $5.66.
Prasad covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Idexx Laboratories, and Coherus Biosciences. According to TipRanks, Prasad has an average return of 5.3% and a 50.00% success rate on recommended stocks.
Revance Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.29, a 187.81% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $37.98 and a one-year low of $5.00. Currently, Revance Therapeutics has an average volume of 1.49M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics (RVNC) Company Description:
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
Read More on RVNC:
- Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
- RVNC Earnings this Week: How Will it Perform?
- Revance price target lowered to $12 from $15 at H.C. Wainwright
- Revance Therapeutics Sets 2024 Goals, Updates Executive Severance Plan
- Revance Therapeutics Sets Executive Compensation for 2024
